Ixoreal Biomed highlights an exploratory placebo-controlled study of SRI-81 Shatavari, alone and combined with KSM-66 Ashwagandha, published in the International Journal of Women’s Health.
|Articles|November 29, 2011
Dec. 21 (new date!) UNPA Webcast: A Pre- and Post-Look at NDI Guidance
As the New Dietary Ingredient (NDI) comment period comes to a close on December 2, an upcoming webcast hosted by the United Natural Products Alliance (UNPA) on December 15 will cover many of the details and next steps.
Advertisement
As the New Dietary Ingredient (NDI) comment period comes to a close on December 2, an upcoming webcast hosted by the United Natural Products Alliance (UNPA) on December 15 will cover many of the details and next steps, including:
- Who filed comments?
- What were the key points of agreement and disagreement?
- Will there be an authoritative ODI list?
- What becomes of probiotics?
- What will an NDI notice really cost?
- How do you know if you should really file an NDI notification? What are your risks if you don’t?
- Is FDA actually enforcing this Guidance as if it were final?
The webcast will take place between 11:00 a.m. and 12:30 p.m. MDT. The cost is $149/person for UNPA members and $295/person for non-members. For more information, contact
Advertisement
Related to this article
Clinical research moves beyond compliance, focusing on smarter trial design, risk-based quality, and “evidence engineering” to deliver decisive, decision-ready results.
The company says the innovation, built on its CoreNhanced BioJourney platform, is designed for beverage and gummy formats.
AuraFen, BILVORA, and IMBE debut at SupplySide Global 2026, and the company will also highlight its CaFi digestive health ingredient.
Horphag Research's Sébastien Bornet breaks down the clinical science behind Robuvit, exploring how the caffeine-free French oak extract supports mitochondrial energy, mood stability, and stress resilience.
Todd Harrison, co-chair of the FDA practice group at Venable LLP, explains how California’s AB 2779 changes date-labeling requirements for supplements, why stability testing matters, and how companies can navigate evolving state rules while advocating for federal uniformity.
FDA's final NDI guidance sets identity and safety expectations. See what AHPA and CRN say remains unresolved and what it means for suppliers.
The company plans to present Organicaps capsules in size 0, 25 years of UC-II, and liquid-filled capsule technology.
Advertisement
Advertisement
Trending on Nutritional Outlook - Supplement, Food & Beverage Manufacturing Trends
1
CoreFX Launches CreaSHLD-IN Shielded Creatine at SupplySide Global 2026
2
Navigating Supplement Ingredients and Claims Regulations in Europe, the US, and Canada
3
Study of SRI-81 Shatavari Reports Sexual Function Gains Versus Placebo in Women
4
FDA Finalizes NDI Guidance on Identity and Safety Information, Leaving Some Industry Concerns Open
5